Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | RARB | P10826 | 2/20 | 0.35 |
| ▸ | RARA | P10276 | 1/20 | 0.35 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15471657 | 0.93 | ESR1 (0.46) | ESR1ESR2HSD17B1RARBRARA | |
| SCHEMBL10916725 | 0.86 | HSD17B1 (0.45) | ESR1ESR2HSD17B1 | |
| SCHEMBL15471654 | 0.86 | ALOX5AP (0.43) | ESR1ESR2HSD17B1RARBALOX5AP | |
| SCHEMBL12603792 | 0.85 | TNKS2 (0.42) | ESR1ESR2IDO1AGXTRIPK1 | |
| SCHEMBL13762684 | 0.84 | ESR1 (0.40) | ESR1ESR2HSD17B1IDO1AGXT | |
| SCHEMBL26036294 | 0.84 | ESR1 (0.43) | ESR1ESR2HSD17B1IDO1AGXT | |
| SCHEMBL17859649 | 0.83 | FFAR1 (0.43) | ESR1ESR2RARBRARARARG | |
| SCHEMBL15471662 | 0.83 | RARB (0.43) | ESR1ESR2RARBRARARARG | |
| SCHEMBL14329412 | 0.83 | RARB (0.43) | ESR1ESR2RARBRARARARG | |
| SCHEMBL19116980 | 0.82 | ESR1 (0.41) | ESR1ESR2RARBRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | DIC CORPORATION (JP) | 2023-08-29 | — | — | US | disclosed |
| US-20230131540-A1 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY ELEMENT AND COMPOUND | DIC CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739270-B2 | Polymerizable compound as well as liquid crystal composition and liquid crystal display device each including polymerizable compound | OCIAD2, PKN2, SKP1 | ESR1 3415/4885ESR2 3116/4885HSD17B1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.